Medios AG is closing the facility of its wholly owned subsidiary, Medios Solutions Aschaffenburg GmbH, and consolidating patient-specific manufacturing at its remaining locations across Germany. The company announced that production has already been relocated, and supplies to pharmacies and hospitals are guaranteed. The Aschaffenburg site accounted for approximately 10% of the Medios Group’s German manufacturing production volume. The closure affects 32 employees, for whom Medios is seeking to provide fair compensation.
The decision comes as the business of patient-specific formulations faces sustained margin pressure, particularly due to price regulatory adjustments. Medios operates a network of six GMP manufacturing facilities for patient-specific therapies in Germany. The Aschaffenburg site had recently been operating at below-average profitability amid declining capacity utilization. Continued economic operation was no longer feasible, and structural renovation work required at the site accelerated the implementation of this decision. The site closure is part of the company’s Operational Excellence Program, which aims to sustainably strengthen profitability.
Thomas Meier, CEO of Medios AG, stated: “With a view to ensuring a reliable supply for our customers and maintaining capacity utilization at all sites, we are now optimizing our successful regional presence strategy and consistently developing it further. With Mannheim and Stuttgart, we have two high-performing Medios sites in southern Germany, ensuring that a reliable supply is maintained.”
The company also highlighted key events for the 2026 financial year, including the Half-Year Financial Report on August 12, the Berenberg and Goldman Sachs 15th German Corporate Conference in Munich from September 21 to 23, the Medios Capital Markets Day in Breda on September 28/29, and the Quarterly Statement as of September 30 on November 10.
Medios AG is a leading provider of Specialty Pharma in Europe, with locations in Germany, the Netherlands, Belgium, and Spain. The company focuses on pioneering individualized medicine to make innovative therapies available to pharmacies, specialist practices, and pharmaceutical companies. Medios AG is Germany's first listed specialty pharmaceutical company, with shares listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and included in the SDAX selection index. More information can be found at www.medios.group.
The original release is available at www.newmediawire.com.
